PMEPA1 guards against TGF-β-mediated prostate cancer bone metastasis  by Blee, Alexandra M. & Huang, Haojie
Asian Journal of Urology (2016) 3, 1e3HOSTED BY Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate/ajurRESEARCH HIGHLIGHTPMEPA1 guards against TGF-b-mediated
prostate cancer bone metastasisIn advanced-stage prostate cancer, bone metastases are
often incurable and cause chronic pain, bone fractures, and
decreased quality of life. Researchers have previously
identified that transforming growth factor-b (TGF-b)
signaling is an important regulator of bone metastases in
prostate cancer and that targeting TGF-b signaling is a
promising therapeutic strategy [1,2]. However, the molec-
ular mechanisms behind TGF-b signaling and prostate cancer
progression remain largely unclear. In a recent study, Four-
nier et al. [3] confirmed that inhibiting TGF-b signaling is
effective in decreasing osteolytic bone metastases of pros-
tate cancer. In addition, this study has identified prostate
transmembrane protein androgen induced-1 (PMEPA1) as a
negative regulator of TGF-b signaling, through a proteasome
degradation-independent mechanism. The authors demon-
strate that epigenetic silencing of PMEPA1 during prostate
cancer progression leads to increased osteolytic metastases
and suggest that PMEPA1 expression is a potential biomarker
for prostate cancer progression.
Canonical TGF-b signaling is known to play differing roles
during cancer progression. In early stages, TGF-b sup-
presses cell proliferation by activating transcription of
cyclin-dependent kinase (CDK) inhibitors and repressing
genes such as MYC and CDK4. In later stages of cancer,
however, TGF-b promotes epithelial-to-mesenchymal
transition (EMT) by upregulating EMT-associated transcrip-
tion factors, and downregulating adhesion proteins [4]. This
secondary malignant outcome of TGF-b signaling is impor-
tant for prostate cancer metastasis, as Fournier et al. [3]
confirmed with the use of SD208, an inhibitor of TGF-b
signaling. Preventative treatment with SD208 significantly
decreased the area of osteolytic lesions in a mouse xeno-
graft model of prostate cancer and improved overall
survival.
During canonical signaling, type 2 TGF-b receptor
(TGFBR2) binds TGF-b, and phosphorylates type 1 TGF-b
receptor (TGFBR1). This initiates a signaling cascade
where phosphorylated receptor-activated SMAD proteins 2
and 3 (SMAD2 and SMAD3) interact with SMAD4, trans-
locate to the nucleus, and activate or represshttp://dx.doi.org/10.1016/j.ajur.2015.11.002
2214-3882/ª 2016 Editorial Office of Asian Journal of Urology. Producti
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-transcription of target genes [4]. The authors identified
PMEPA1 as a target of SMAD3/4 and specificity protein 1
(SP1) that is transcriptionally activated by TGF-b signaling
(Fig. 1, left). Based on prostate and breast cancer data-
sets accessed through Oncomine, the authors found that
lower expression of PMEPA1 was linked with poor patient
outcomes such as earlier recurrence after treatment,
shorter time to metastasis, and decreased overall sur-
vival. Their findings are among the first to identify PMEPA1
as a key component of prostate cancer progression and
metastasis.
It has previously been demonstrated that PMEPA1
negatively regulates TGF-b signaling [5] as well as androgen
receptor (AR)-mediated signaling [6]. Further study by
Fournier et al. [3] revealed a possible mechanism for
PMEPA1-mediated inhibition of TGF-b signaling in prostate
cancer, that explains the clinical significance of PMEPA1
loss. The authors demonstrated that only the membrane-
bound isoform of PMEPA1 inhibited TGF-b signaling, and
that this activity required both the SMAD interacting motif
(SIM) and PPxY domain (for interaction with HECT E3
ubiquitin ligases) of PMEPA1. They proceeded to find that
this isoform of PMEPA1 interacted with both SMAD2 and
SMAD3, as well as multiple HECT E3 ubiquitin ligases known
to negatively regulate TGF-b signaling, including NEDD4-1,
NEDD4-2, AIP-4, and SMURF2. In particular, Fournier et al.
[3] demonstrated that PMEPA1 was important for associa-
tion of SMAD2 and SMURF2 and subsequent inhibition of
TGF-b signaling, independent of proteasome-mediated
protein degradation (Fig. 1, left). Their data aligns well
with a previously described proteasome-independent
mechanism of TGF-b signaling inhibition [7]. In this case,
SMURF2 mono-ubiquitinates SMAD2 and 3 at several resi-
dues and prevents formation of SMAD complexes and
localization to the nucleus, effectively inhibiting TGF-b
signaling.
Fournier et al. [3] confirmed their findings in the model
prostate cancer cell line PC-3. Upon loss of PMEPA1, cells
exhibited increased TGF-b signaling marked by increased
SMAD2 phosphorylation and nuclear localization. Similarlyon and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
Figure 1 PMEPA1 antagonizes TGF-b signaling-mediated prostate cancer cell metastases. Left, membrane-bound PMEPA1 acts as
a negative regulator of TGF-b signaling by binding HECT E3 ligases and SMAD proteins, ultimately resulting in decreased bone
metastases. Right, during prostate cancer progression, the promoter of the PMEPA1 gene is methylated. As a result, TGF-b signaling
proceeds without inhibition, ultimately leading to increased bone metastases. PMEPA1, prostate transmembrane protein androgen
induced-1; TGF-b, transforming growth factor-b; TGFBR1, type 1 TGF-b receptor; TGFBR2, type 2 TGF-b receptor.
2 Research highlightin a xenograft mouse model, increased osteolytic metas-
tases were observed upon loss of PMEPA1.
The work by Fournier et al. [3] describes a new mech-
anism for inhibition of TGF-b signaling by PMEPA1. The
authors suggest that in advanced-stage prostate cancer,
loss of PMEPA1 expression due to AR-driven DNA methyl-
ation [8] leads to uninhibited TGF-b signaling and increased
bone metastases (Fig. 1, right). Their work is relevant as it
provides a new mechanism for regulation of TGF-b signaling
in prostate cancer and identifies PMEPA1 expression as a
biomarker for prostate cancer progression and metastasis.
However, there remains a need for more extensive study of
clinical prostate cancer samples to identify how frequently
loss of PMEPA1 correlates with bone metastases and
decreased patient survival. In addition, further study is
needed to better identify the relationship between both
TGF-b and AR signaling with regards to PMEPA1 expression.
While TGF-b signaling increases PMEPA1 expression, AR-
mediated signaling can lead to promoter methylation that
decreases PMEPA1 expression. How these two pathways
interact during prostate cancer progression remains to be
understood. Findings from these and other investigations
may lead to both better detection and treatment of met-
astatic prostate cancer.Conflicts of interest
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